NCT02743780View on ClinicalTrials.gov

A Three Part Study of MGV354 in Ocular Hypertension or Glaucoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

191

Participants

Timeline

Start Date

March 2, 2016

Primary Completion Date

September 20, 2016

Study Completion Date

September 20, 2016

Conditions
Ocular HypertensionOpen-Angle Glaucoma
Interventions
DRUG

MGV354 ophthalmic suspension

DRUG

MGV354 placebo

Inactive ingredients used as placebo comparator

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
collaborator

Novartis Institute for BioMedical Research

UNKNOWN

lead

Alcon Research

INDUSTRY